The meeting approved all resolutions, including a new Rights Plan, increased director remuneration, and CEO options, with strong shareholder support. Strategic focus is on advancing clinical programs, expanding the board and executive team, and maintaining robust governance. Key milestones in clinical development are expected soon.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.